trial

Differences in Schizophrenia With One-month and 3-month Paliperidone Palmitate Treatment

NCTId NCT04754750
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1, Phase 2 · Completed
Enrollment 72 (actual)
Sponsored by Calo Psychiatric Center
Primary completion 2017-06
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1, Phase 2
Status
Completed
Enrollment
72 (actual)
Study type
Interventional
Allocation
Non Randomized
Model
Sequential
Masking
None
Start
2015-01
Primary completion
2017-06
Eligibility
ALL · 30 Years · 69 Years

Interventions & indications

Drugs
Paliperidone

Sponsors

Calo Psychiatric CenterLead Sponsor

Investigators

1
For-Wey Lung, MD, ScDPrincipal Investigator

Sites

0 total

Linked catalysts

1
Differences in Schizophrenia With One-month and 3-month Paliperidone Palmitate T — primary completion2017-06

Facts & assertions

4 sourced
Enrollment
72
Phase
PHASE1,PHASE2
Primary Completion Date
2017-06
Status
COMPLETED
relationships
The graph out of here
drug
Paliperidone
drug
lead_sponsor
Calo Psychiatric Center
company
indication
Schizophrenics
indication
Social Adjustment
indication
investigator
For-Wey Lung, MD, ScD
person